about
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateTRU-015, a fusion protein derived from an anti-CD20 antibody, for the treatment of rheumatoid arthritisEffects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseasesEffect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials.Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patientsEfficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosusSafety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis.MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial.Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE.Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab.Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial.Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical reviewA randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoTo switch or not to switch after a poor response to a TNFα blocker? It is not only a matter of ACR20 OR ACR50.Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs.Assessing the safety of biologic agents in patients with rheumatoid arthritis.German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.Spectrum of Uveitis in A German Tertiary Center: Review of 474 Consecutive Patients.Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative.Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis.Increased frequency of JC-polyomavirus detection in rheumatoid arthritis patients treated with multiple biologics.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure.Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID).
P50
Q26859134-8DFF833F-0454-453E-A03A-81D800A89F75Q28272698-55063BA8-BBD7-46B7-9E13-5DB10569C212Q28744267-12A87919-58D8-402B-994A-1A8ABCD36E3BQ31151183-4B89C40A-08B8-4319-8CFA-FFB97AB41D48Q33765608-5415856F-4A92-42E9-8132-1233A05D7106Q34056237-47CEC42F-F4DE-406A-B523-4445FA2E7921Q34464260-CDBC184B-0595-4C91-B793-A3034F0473F5Q35557832-921D4296-0989-429A-839A-A3D7CA4F8456Q35569500-F26FF03B-B669-4C3A-9BFA-3213ABD232D8Q35605418-6141415B-4140-40D8-8CAF-0C42EC58191EQ35751550-8472E645-BD99-47BE-ACB8-B62EE1015942Q36677277-399F9A5A-DBE8-4FF6-BC06-94F73CF1CAC6Q36919914-6A43224A-31BE-47AF-9861-2A537E1A29C7Q36968747-729B674C-BAA1-45BB-B6B3-9487CCC5A821Q37158791-ACE44613-4E78-4A00-A4CD-01E804760DAFQ37465508-9959EA53-5B44-4BB9-9E7F-B569C4552098Q37950781-896FCA23-5E30-40FB-BA6E-9D421E9F3401Q38020459-EAF97509-E7BA-413F-8BD1-7CED50A2B71AQ38020463-5CABDB21-21C6-4C82-895A-011C41FB5BCFQ38128726-FBF2BF68-1B0D-49B5-87D0-89DD4CD7CA7EQ38373883-9274D27B-201F-4662-9820-09398C5045C6Q38777496-B9D489A2-771D-4B3D-9D8D-63BC7DC77076Q38828876-1F29B22F-4A66-41DA-8665-1793B27EA0C4Q39039495-C10E45A8-F77A-42B5-B85B-7FC87F64C536Q40305889-0A7904EA-3D83-41FE-8186-69A00264054BQ40327635-4F7982CE-8024-4975-869E-041C5AEB29D3Q41146132-A193E3F2-ED93-48C1-AB0D-9272F250BD0AQ42090806-89EBF804-FEDE-4541-9B93-B9A38C121DBCQ42689974-1A64BD27-5F1A-4F60-9EF7-4EAAA975F5E3Q43855238-9BEB34AB-1F5D-410B-BBBB-FDCAC3CC877C
P50
description
researcher ORCID ID = 0000-0001-5984-6922
@en
wetenschapper
@nl
name
Andrea Rubbert-Roth
@ast
Andrea Rubbert-Roth
@en
Andrea Rubbert-Roth
@es
Andrea Rubbert-Roth
@nl
type
label
Andrea Rubbert-Roth
@ast
Andrea Rubbert-Roth
@en
Andrea Rubbert-Roth
@es
Andrea Rubbert-Roth
@nl
prefLabel
Andrea Rubbert-Roth
@ast
Andrea Rubbert-Roth
@en
Andrea Rubbert-Roth
@es
Andrea Rubbert-Roth
@nl
P214
P227
P101
P1053
E-5599-2016
P106
P21
P214
P227
P31
P3829
P496
0000-0001-5984-6922
P734
P7859
viaf-217551843